Inactive Instrument

News Checkmate Pharmaceuticals, Inc.

Stocks

CMPI

US1628181083

Biotechnology & Medical Research

All News

22-05-31	Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
22-05-31	CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
22-05-31	Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	CI
22-05-31	Checkmate Pharmaceuticals, Inc. Announces Board Changes	CI
22-05-31	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	CI
22-05-31	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	CI
22-05-26	Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	CI
22-05-26	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
22-05-26	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	CI
22-05-26	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	GL
22-05-17	CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI	BU
22-05-12	CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
22-05-12	Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-05-12	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update	AQ
22-05-12	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update	GL
22-05-05	CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI	BU
22-04-20	BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	MT
22-04-19	Checkmate Pharmaceuticals : TENDER AND SUPPORT AGREEMENT - Form 8-K	PU
22-04-19	CHECKMATE PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
22-04-19	Checkmate Pharmaceuticals : Joint Press Release, issued April 19, 2022 - Form 8-K	PU
22-04-19	CHECKMATE PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22-04-19	Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal	DJ
22-04-19	Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types	PR
22-04-18	Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others for approximately $250 million.	CI
22-04-08	Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research Annual Meeting	CI